Results 101 to 110 of about 48,812 (228)

Refining the treatment of immune checkpoint inhibitor–associated myocarditis: Challenges, innovations and rechallenge considerations

British Journal of Pharmacology, EarlyView.
Immune checkpoint inhibitor (ICI)‐associated myocarditis has emerged as a severe and clinically complex immune‐related toxicity that poses significant challenges for therapeutic decision‐making in routine cardio‐oncological care. High‐dose corticosteroids remain the first‐line therapy, yet their timing, dosage and tapering require careful clinical ...
Raluca I. Mincu, Lisa Zimmer, Dimitra Vlachopoulou, Elias Haj‐Yehia, Julia Hoffmann, Lars Michel, Elisabeth Livingstone, Dirk Schadendorf, Alpaslan Tasdogan, Matthias Totzeck, Tienush Rassaf   +10 more
wiley   +1 more source

A retrospective analysis of High-Dose Interleukin-2 (HD IL-2) following Ipilimumab in metastatic melanoma

Journal for ImmunoTherapy of Cancer, 2016
Background High dose interleukin-2 (HD IL-2) can induce durable responses in a subset of patients leading to long-term survival. Immune checkpoint blockade (ICB) has demonstrated similarly durable responses in a larger proportion of patients.
Sandra Aung, Sigrun Hallmeyer, David F. McDermott, Joseph I. Clark, Howard L. Kaufman, Gregory A. Daniels, Sapna P. Patel, John M. Kirkwood, Ryan J. Sullivan, Marc S. Ernstoff, Brendan D. Curti, Elizabeth I. Buchbinder, Rene Gonzalez, John M. Richart, Anasuya Gunturi, Jessica Perritt, Janice Dutcher, Girald P. Miletello, Joe Lutzky, Michael A. Morse   +19 more
doaj   +1 more source

Immune checkpoint inhibitor‐induced arrhythmias: Mechanistic insights from clinical and preclinical studies

British Journal of Pharmacology, EarlyView.
Immune checkpoint inhibitors (ICIs) have transformed cancer therapy, but their efficacy continues to be limited by immune‐related adverse events. Among these, ICI‐induced cardiac arrhythmias are increasingly recognised as a major adverse reaction, encompassing a broad spectrum of clinical phenotypes, including conduction blocks, atrial fibrillation and
Anand R. Ramalingam, Zoltán Márton Köhler, Péter Ferdinandy, Zoltán V. Varga   +3 more
wiley   +1 more source

Arrhythmias associated with immune checkpoint inhibitor therapy—A clinical perspective

British Journal of Pharmacology, EarlyView.
Immune checkpoint inhibitors (ICIs) have transformed cancer therapy but are associated with a growing spectrum of cardiovascular immune‐related adverse events. Among these, arrhythmias represent a rare yet potentially life‐threatening complication. ICI‐induced arrhythmias encompass a wide clinical spectrum, including atrial arrhythmias, conduction ...
Dong Wang, Melanie Ricke‐Hoch, David Duncker, Johann Bauersachs, Dominik Berliner   +4 more
wiley   +1 more source

Rechallenge of ipilimumab and nivolumab in advanced melanoma patients after previous ipilimumab-based therapy [PDF]

BACKGROUND: Ipilimumab+nivolumab (IPINIVO) can induce durable responses in advanced melanoma, but many patients experience progression at some point. It is currently unknown to what extent these patients benefit from IPINIVO rechallenge.
van der Veldt, A A M, Suijkerbuijk, K. P.M., van den Berkmortel, F W P J, Bloem, M., Hospers, G A P, van Dijk, E. J., Bos, C., Nienhuis, H H, Aarts, M J B, Vreugdenhil, G, van Dijk, E J, Blank, C U, Ros, M. M., van den Berkmortel, F. W.P.J., Nienhuis, H. H., van den Eertwegh, A. J.M., Blank, C. U., Stevense-den Boer, A. M., Haanen, J. B., Bloem, M, Bos, C, Kapiteijn, E, Boers-Sonderen, M. J., Kapiteijn, E., Wouters, M W J M, Hospers, G. A.P., Piersma, D, de Groot, J. W.B., Stevense-den Boer, A M, van den Eertwegh, A J M, de Groot, J W B, van Rijn, R S, Piersma, D., Kamphuis, A. M., Boers-Sonderen, M J, Suijkerbuijk, K P M, Wouters, M. W.J.M., Blokx, W A M, Haanen, J B, Aarts, M. J.B., Blokx, W. A.M., van Rijn, R. S., Vreugdenhil, G., Kamphuis, A M, Ros, M M, van der Veldt, A. A.M.   +45 more
core   +1 more source

Ipilimumab-induced hypophysitis involving the optic tracts and tuber cinereum evaluated using 3D fluid-attenuated inversion recovery

Radiology Case Reports, 2018
Ipilimumab, a human monoclonal antibody against cytotoxic T-lymphocyte antigen 4, was approved by the U.S. FDA (Food and Drug Administration) in 2011 for the treatment of unresectable or metastatic malignant melanoma.
Fumine Tanaka, MD, Ryota Kogue, MD, Masayuki Maeda, MD, PhD, Maki Umino, MD, PhD, Yasuo Nakai, MD, Atsuro Takeshita, MD, Hajime Sakuma, MD, PhD   +6 more
doaj   +1 more source

Genomic Evolution and Immune Contexture With Therapeutic Relevance in Pancreatic Neuroendocrine Neoplasms

Cancer Science, EarlyView.
Lineage‐dependent immunogenomic landscapes and biologically informed therapy in pancreatic neuroendocrine neoplasms. Pancreatic neuroendocrine neoplasms display lineage‐dependent immunogenomic landscapes, in which genomic alterations, epigenetic states, antigen‐presentation status, immune‐cell infiltration, and suppressive microenvironments co‐evolve ...
Yohei Tabe, Eito Nakagawa, Daisuke Asano, Eriko Katsuta, Daisuke Ban, Shogo Kumagai   +5 more
wiley   +1 more source

Randomized, Open-Label Phase II Study Evaluating the Efficacy and Safety of Talimogene Laherparepvec in Combination With Ipilimumab Versus Ipilimumab Alone in Patients With Advanced, Unresectable Melanoma [PDF]

, 2018
Purpose We evaluated the combination of talimogene laherparepvec plus ipilimumab versus ipilimumab alone in patients with advanced melanoma in a phase II study.
Theodore F. Logan, Jennifer Gansert, Lisa Chen, John Glaspy, Jason Chesney, Axel Hauschild, Puzanov, Igor, Kaufman, Howard L, Kim, Jenny J, Mohammed M. Milhem, Jenny J. Kim, Chen, Lisa, Hamid, Omid, Parminder Singh, Frances Collichio, Philip Friedlander, Logan, Theodore F, Andtbacka, Robert HI, Hauschild, Axel, Omid Hamid, Merrick Ross, Gansert, Jennifer, Howard L. Kaufman, Robert H.I. Andtbacka, Igor Puzanov, Collichio, Frances, Lebbé, Celeste, Celeste Lebbé, Friedlander, Philip, Milhem, Mohammed M, Chesney, Jason, Glaspy, John, Claus Garbe, Garbe, Claus, Ross, Merrick, Singh, Parminder   +35 more
core   +1 more source

Advances in Radiotherapy for Neoadjuvant Therapy of Stage III Non‐Small Cell Lung Cancer

Cancer Science, EarlyView.
This review summarizes three neoadjuvant radiotherapy techniques for stage III NSCLC, highlighting SFRT's low‐toxicity dual immune‐tumor control benefits and radioimmunotherapy's superior pathological response to guide precise multimodal treatment. ABSTRACT This review aims to systematically summarize the mechanisms of action, clinical evolution, and ...
Qinrong Mao, Yuanchun Yu, Yan Fang, Shaofeng Zhu, Chengjin Tang, Jing Cai   +5 more
wiley   +1 more source

Unusual pulmonary toxicity of ipilimumab treated by macrolides

, 2015
Introduction: Ipilimumab is a human monoclonal antibody that blocks cytotoxic-T-lymphocyte-associated antigen 4 (CTLA-4) and promotes antitumour immunity. It has recently been approved for the treatment of metastatic melanoma patients.
Baurain, Jean-François, Colin, Geoffrey, Cornelis, Frank, Mailleux, Marie   +3 more
core   +1 more source